<DOC>
	<DOCNO>NCT01990729</DOCNO>
	<brief_summary>To study safety efficacy ARTRA ( glucosamine chondroitin sulfate ) treatment non-specific low-back pain lumbosacral localization ambulatory care .</brief_summary>
	<brief_title>Efficacy Safety ARTRA ( Glucosamine Plus Chondroitin Sulfate Combination ) Treatment Chronic Low Back Pain</brief_title>
	<detailed_description>We enrol patient 40 65 year age low back pain least 12 week pain intensity &gt; 3 0-10 point visual analogue scale ( VAS ) . Major exclusion criterion presence fibromyalgia , degenerative spondylolisthesis , alcohol and/or drug abuse . All patient treat ARTRA ( combination glucosamine hydrochloride 500 mg chondroitin sulfate 500 mg tab ; Unipharm Inc. ) dose 1 tab bid first month 1 tab daily next two month . The primary endpoint pain intensity ( rest movement ) measure 0-10 point VAS . Secondary endpoint include Oswestry Disability Index , patient global assessment efficacy ( 0-5 scale ) NSAID consumption .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Hydroquinone</mesh_term>
	<criteria>1 . Patients aged 4065 year , inclusively . 2 . Pain intensity accord Visual Analogue Scale ( VAS ) &gt; 3 point . 3 . Duration back pain &gt; 12 week . 4 . Pain reinforcement movement lumbar spine . 5 . Osteoarthritis , spondylarthrosis , osteochondrosis . 6 . Given write Informed consent form participation study . 7 . Treatment ARTRA 1 . History allergic reaction chondroprotectors . 2 . Participation another clinical study within 30 day screen study . 3 . Fibromyalgia . 4 . Active neoplastic disease , history neoplastic disease within 3 year screen . 5 . Paget 's disease . 6 . Degenerative spondylolisthesis . 7 . Administration anticonvulsant , antidepressant , barbiturate , anxiolytic , muscle relaxant drug one week prior screen . 8 . History alcohol drug abuse . 9 . Frequent episodes nausea , dyspepsia , pain epigastric region , diarrhea , face extremity edema , dizziness headache . 10 . History disease , opinion investigator , might confound result study pose additional risk subject participation study 11 . Clinically significant renal disorder .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>